Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04563026 · ClinicalTrials.gov registry record · Phase 2
A Phase 2b Study in Subjects With Alcoholic Hepatitis to Evaluate Safety and Efficacy of DUR-928 Treatment
A Phase 2 study, sponsored by Durect.
- Completed
- Registry status
- Phase 2
- Development phase
- 307
- Enrollment target
NCT04563026 is a Phase 2 study that has completed, run by Durect. The registered enrollment target is 307 participants.
The verdict
NCT04563026, a Phase 2 study, has completed, sponsored by Durect.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 307 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo-controlled, phase 2b clinical Trial evaluating Safety and Efficacy of DUR-928 (an experimental medication) in Patients with Alcoholic Hepatitis (AH).
Interventions
- DRUG DUR-928 30 mg
- DRUG DUR-928 90 mg
- DRUG Placebo+ Standard of Care (SOC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 307 participants |
| Start Date | 2021-01-22 |
| Est. Completion | 2023-09-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04563026
The ClinicalTrials.gov registry entry for NCT04563026 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 307 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Durect, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which DUR-928 30 mg is the first listed.
NCT04563026 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04563026 about?
NCT04563026 is a clinical study titled "A Phase 2b Study in Subjects With Alcoholic Hepatitis to Evaluate Safety and Efficacy of DUR-928 Treatment". This is a randomized, double-blind, placebo-controlled, phase 2b clinical Trial evaluating Safety and Efficacy of DUR-928 (an experimental medication) in Patients with Alcoholic Hepatitis (AH).
What is the current status of trial NCT04563026?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 307 participants. The study started on 2021-01-22. Estimated completion is 2023-09-06.
What interventions are being tested in trial NCT04563026?
The interventions under investigation include: DUR-928 30 mg (DRUG), DUR-928 90 mg (DRUG), Placebo+ Standard of Care (SOC) (DRUG).
Who is sponsoring clinical trial NCT04563026?
This trial is sponsored by Durect, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.